Non-concurrent controls occur in adaptive platform trials. Our paper gives a new more rigorous definition based on randomization cohort rather than time. Cohort adjustment and implications for databases & software are discussed.
@austrim_cre@TrialsCentre
https://t.co/JrnFnWiSkb
@JAMAOnc Treatments that improve survival provide greater opportunity for adverse events to occur. See the Limitations Section: "improved survival with ARSIs could manifest as a higher captured incidence of CV events. It is impossible to account for this given lack of time to event data"
Recent @TheLancet trial uses confidence distribution to conclude “the confidence that the risk ratio is lower than 1 is 97.2%”. Full confidence distribution plot in supplementary material. Excellent way to present trial results as described in Reference 24
https://t.co/x5CVoOpyeE
@KertViele @syctong @GuyattGH I agree that small concurrently randomised cohorts are a challenge for reporting. I would interpret this as an argument for avoiding design features that produce small cohorts e.g. I would argue we should avoid frequent interim analyses that lead to frequent design adaptations
@f2harrell @vandy_biostat Not always. If design choice reflects prior belief then Bayesian inference is affected by multiplicity. As Kass & Wasserstein said (JASA 1996 p.1359): “It could be argued that choice of design is informative and so the prior should depend on the design”
@f2harrell @vandy_biostat Note that absence of multiplicity issues in Bayesian inference requires the important assumption that you would use the same prior regardless of the design. Reference priors contravene this assumption, yielding different Bayesian inferences for sequential and fixed designs
“Removing the advanced mathematics prerequisite does nothing to address the decline in mathematics enrolments at schools and sends the wrong signal to students.”
https://t.co/uBOnu6gE4F
@KertViele Sounds like a great session. I agree that if anyone’s saying data should be thrown away that’s problematic. Also important to recognise that different types of data have different levels of quality. If we pool them then we need to understand the relative contributions of each
@GuyattGH Here is closely related research conducted independently by PhD student Anne Lyngholm Soerensen published last year. Clearly an important topic
https://t.co/tZSFTf7D9c
@JasonConnorPhD@ADAlthousePhD You might look at these two old papers (and papers citing them), they sound relevant
https://t.co/bVhZH9SVyv
https://t.co/hT9k4jBGq8
@predict_addict@austrim_cre@TrialsCentre Thanks for the interesting references but you are talking about prediction whereas I'm talking about inference (a common difference between data scientists and statisticians). It's unclear what you mean by "lack validity" when the context is inference from a randomized experiment
Confidence distributions are distributional summaries of evidence. They’re like Bayesian posteriors but without prior distribution assumptions. I wrote a tutorial paper in Statistics in Medicine for clinical trial statisticians @austrim_cre@TrialsCentre
https://t.co/sOk09yDpB3
@lakens Your opening argument is based on: “it is just as likely to observe a p-value of 0.001 as it is to observe a p-value of 0.999”. Both of these values have zero probability of being observed (for a continuous p-value distribution) so I’m not sure what the point is you are making
@syctong Need to be careful of non-proportional odds in such an analysis. The odds ratio for “considerable improvement” is about 12.4 compared to 4.7 for survival, yet they are assumed to be the same. Might be chance variation but important to check or else the odds ratio could be biased